Exscientia plc (0RK.SG)

3,6800 -0,1600 (-4,17%) Börsenschluss: 09:59PM CEST

Exscientia plc

The Schrödinger Building
Oxford Science Park
Oxford OX4 4GE
United Kingdom
44 18 6581 8941
https://www.exscientia.ai

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 483

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. David Hallett Ph.D.	Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director	N/A	N/A	1969
Mr. Ben R. Taylor	CFO, Chief Strategy Officer & Executive Director	490,24k	N/A	1977
Dr. Michael Krams M.D.	Chief Medical Officer	N/A	N/A	1961
Ms. Eileen Jennings-Brown	Chief Information Officer	N/A	N/A	N/A
Ms. Sara Sherman	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Dan Ireland	Vice President of Legal & Company Secretary	N/A	N/A	N/A
Mr. Parker Moss	Executive Vice President of Corporate Development	N/A	N/A	N/A
Ms. Caroline Rowland	Chief People Officer	N/A	N/A	N/A
Mr. Richard Law	Chief Business Officer	N/A	N/A	N/A
Dr. John P. Overington Ph.D.	Chief Data Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité – Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Corporate Governance

Exscientia plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.